Cancer Drug Development in Europe: A Selection of New Agents Under Development at the European Drug Development Network

From may 99, three european leaders in anti-cancer drug development (EORTC, Cancer Research UK, SENDO) have got together to form a network of collaborating groups: the European Drug Development Network. The member organisations have all agreed to join their efforts in developing new drugs. They have acquired a great and efficient expertise in anticancer drug development covering all aspects from drug screening to refinement of trial methodology and translational research. In this paper, the most interesting drugs under development in each of the three organisations are being described and discussed.

[1]  E. Sausville,et al.  Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. , 2000, Cancer research.

[2]  M. Zucchetti,et al.  Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. Eck,et al.  Characterization of recombinant and plant-derived mistletoe lectin and their B-chains. , 1999, European journal of biochemistry.

[4]  M. Stevens,et al.  2-(4-Aminophenyl)benzothiazoles: Agents with Selective and Potent Antitumour Activity in vitro and in vivo , 1999 .

[5]  S. McKeown,et al.  Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. , 1998, International journal of radiation oncology, biology, physics.

[6]  K. Paull,et al.  Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo. , 1998, British Journal of Cancer.

[7]  R. Himes,et al.  Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action , 1998 .

[8]  H. Suzuki,et al.  An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. , 1998, Hybridoma.

[9]  H. Koepsell,et al.  Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  K. Paull,et al.  2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity. , 1998, British Journal of Cancer.

[11]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[12]  A. Photiou,et al.  Antibody-directed enzyme prodrug therapy (ADEPT). , 1996, International journal of oncology.

[13]  J. Riou,et al.  From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. , 1996, European journal of cancer.

[14]  W. R. Bishop,et al.  Novel Tricyclic Inhibitors of Farnesyl Protein Transferase , 1995, The Journal of Biological Chemistry.

[15]  M. D’Incalci,et al.  108 Antiproliferative activity and mode of action of novel compounds of marine origin , 1995 .

[16]  B. Baguley,et al.  Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 1994: PHARMACOKINETIC/CYTOKINETIC PRINCIPLES IN THE CHEMOTHERAPY OF SOLID TUMOURS , 1995, Clinical and experimental pharmacology & physiology.

[17]  J. Schlom,et al.  A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate , 1995, International journal of cancer.

[18]  W. L. Shupert,et al.  Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. , 1995, Cancer research.

[19]  E. Lazarides,et al.  Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. , 1995, Cancer research.

[20]  L. Neckers,et al.  Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  L. H. Patterson.  Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent , 1993, Cancer and Metastasis Reviews.

[22]  W. Denny,et al.  Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the colon 38 active agent 9-oxo-9H-xanthene-4-acetic acid. , 1991, Journal of medicinal chemistry.

[23]  M. Dolan,et al.  Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. , 1991, Cancer research.

[24]  W. Fiers,et al.  Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. , 1990, Cancer research.

[25]  M. Dolan,et al.  Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[26]  C. Fowler,et al.  The fate of G3pT1 bladder cancer. , 1989, British journal of urology.

[27]  K. Bagshawe.  The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites. , 1989, British Journal of Cancer.

[28]  J. Gavin,et al.  Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. , 1989, Journal of the National Cancer Institute.

[29]  W. Denny,et al.  Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. , 1989, Journal of medicinal chemistry.

[30]  D. Alberts,et al.  Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 , 1989, Experientia.

[31]  J. Double,et al.  Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. , 1989, Journal of the National Cancer Institute.

[32]  C. Springer,et al.  A cytotoxic agent can be generated selectively at cancer sites. , 1988, British Journal of Cancer.

[33]  W. Duncan,et al.  Treatment of superficial (T1) tumours of the bladder by radical radiotherapy. , 1986, British journal of urology.

[34]  G. Cragg,et al.  Isolation and structure of combretastatin , 1982 .

[35]  A. McPhail,et al.  Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 , 1966 .

[36]  L. Neckers,et al.  The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin , 1998, Cancer Chemotherapy and Pharmacology.

[37]  H. van Tinteren,et al.  Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy. , 1995, European journal of cancer.

[38]  M. Stanley,et al.  Human papillomaviruses and cervical cancer : biology and immunology , 1994 .

[39]  J. Denekamp,et al.  Angiogenic attack as a therapeutic strategy for cancer. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[40]  M. Dolan,et al.  Modulation of mammalian O6-alkylguanine-DNA alkyltransferase in vivo by O6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. , 1990, Cancer communications.